Loading clinical trials...
Loading clinical trials...
Niraparib is a PARP inhibitor. The study is a 2:1 randomized, double-blind, placebo-controlled, multi-center,phase 3 study of ZL-2306 (niraparib) as maintenance therapy following first-line platinum-b...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Zai Lab (Shanghai) Co., Ltd.
NCT06646276 · Extensive-Stage Small Cell Lung Cancer
NCT04397003 · Extensive-stage Small Cell Lung Cancer
NCT07328490 · Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, and more
NCT04373369 · Extensive-stage Small Cell Lung Cancer
NCT04774380 · Extensive-stage Small Cell Lung Cancer
Anhui Provincal Hospital
Hefei, Anhui
Beijing Cancer Hospital
Beijing, Beijing Municipality
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions